title: Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia.
abstract: Prefrontal serotonin 2A receptors (5-HT2A Rs) have been linked to the pathogenesis and treatment of schizophrenia. Many antipsychotics fully occupy 5-HT2A R at clinical relevant doses, and activation of 5-HT2A receptors by lysergic acid diethylamide (LSD) and LSD-like drugs induces a schizophrenia-like psychosis in humans. Subchronic phencyclidine (PCP) administration is a well-established model for schizophrenia-like symptoms in rodents. The aim of the present study was to investigate whether subchronic PCP administration changes expression, binding, or functionality of cortical 5-HT2A Rs. As a measure of 5-HT2A R functionality, we used the 5-HT2A R agonist 2,5-dimethoxy-4-iodoamphetamine (DOI)-induced head-twitch response (HTR) and mRNA expression of the immediate-early genes (IEGs) activity-related cytoskeletal associated-protein (Arc), c-fos, and early growth response protein 2 (egr-2) in the frontal cortex. Mice were treated with PCP (10 mg/kg) or saline for 10 days, followed by a 5-day washout period. The PCP pretreatment increased the overall induction of HTR and frontal cortex IEG mRNA expression following a single challenge with DOI. These functional changes were not associated with changes in 5-HT2A R binding. Also, binding of the 5-HT1A R and the 5-HT transporter was unaffected. Finally, basal mRNA level of Arc was increased in the prefrontal cortex after subchronic PCP administration as revealed with in situ hybridization. Together these findings indicate that PCP administration produces changes in the brain that result in an increase in the absolute effect of DOI. Therefore, neurotransmission involving the 5-HT2A R could contribute to the behavioral deficits observed after PCP treatment. © 2013 Wiley Periodicals, Inc.
authors: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
authors: Martin A
authors: MA
authors: Santini
authors: Cecilia
authors: C
authors: Ratner
authors: Susana
authors: S
authors: Aznar
authors: Anders B
authors: AB
authors: Klein
authors: Gitte M
authors: GM
authors: Knudsen
authors: Jens D
authors: JD
authors: Mikkelsen
mesh_terms: D000386:AIDS-Related Complex / Q000235:genetics / Q000378:metabolism; D000662:Amphetamines / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000502:physiology; D017781:Genes, Immediate-Early / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010622:Phencyclidine / Q000494:pharmacology* / Q000633:toxicity; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism*; D012559:Schizophrenia / Q000139:chemically induced* / Q000473:pathology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors
chemical_list: D000662:Amphetamines; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D044348:Receptors, Serotonin, 5-HT2; D017366:Serotonin Receptor Agonists; D010622:Phencyclidine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine